| 0.8538 -0.006 (-0.72%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.38  |
1-year : | 1.63 |
| Resists | First : | 1.18 |
Second : | 1.39 |
| Pivot price | 1.02 |
|||
| Supports | First : | 0.83 | Second : | 0.69 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 1.08 |
| MA(100) : | 1.99 |
MA(250) : | 8.32 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 6.3 |
| RSI | RSI(14): 21.4 |
|||
| 52-week | High : | 60.47 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ REVB ] has closed above bottom band by 17.8%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.91 | 0.91 - 0.92 |
| Low: | 0.83 - 0.84 | 0.84 - 0.85 |
| Close: | 0.84 - 0.86 | 0.86 - 0.87 |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Wed, 12 Nov 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 - El Paso Times
Thu, 06 Nov 2025
Revelation Biosciences (NASDAQ: REVB) believes cash sufficient to fund operations through Q3 2026 - Stock Titan
Wed, 29 Oct 2025
Revelation Bio (NASDAQ: REVB) sets Oct 29 record date; Special Meeting on Dec 3 - Stock Titan
Wed, 29 Oct 2025
Revelation Biosciences Inc Cancels Special Meeting and Sets New Date - TradingView
Tue, 30 Sep 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 - St. Cloud Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 11.8 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 67 (K) |
| EPS | 81.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.7 % |
| Return on Equity (ttm) | -118.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | 0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|